Dianthus Therapeutics Stock (NASDAQ: DNTH)

Dianthus Therapeutics

DIANTHUS THERAPEUTICS INC

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

DNTH

DXYZ

FLIC

POWL

QDEL

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

ULTA, Ulta Beauty

EOSE

ESTC

HSHP

ULTA

Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Penny Stocks

Small Cap

Intraday Update

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CUTR

CZOO

EGOX

FRSX

GRDI

GRFS

GTBP

ISPR

JOAN

LAAC

LICY

LULU

LXEH

MRNO

NKTX

NVFY

OCGN

OTLK

RETO

SINT

SLNA

SMLP

TROO

YTEN

Shares of  Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics Inc

Press Releases

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

Management

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

Earnings

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Analyst Ratings

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

Altimmune

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cidara Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Jyong Biotech

MeiraGTx Hldgs

Myriad Genetics

Relay Therapeutics

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tyra Biosciences

Upstream Bio

Xencor

Baird

HC Wainwright & Co.

Wedbush

Guggenheim

Oppenheimer

Comments

Dianthus Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell